Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Female MRs Increasing: Education Center Report
September 23, 2002
- Kurabo Ties Up with Agilent Technologies for Contract Gene Analysis
September 23, 2002
- Generic Manufacturers Face Problems with Distribution
September 23, 2002
- Need for Spreading CAPD Stressed: Terumo Seminar
September 23, 2002
- Overseas Clinical Trials of Ono's Elaspol Suspended
September 23, 2002
- OTC NEWS IN BRIEF
September 23, 2002
- Daiichi to Restructure Global R&D System
September 23, 2002
- PRESS SEMINAR
September 23, 2002
- Taisho Toyama Pharm to Be Created Next Month
September 23, 2002
- Orthopaedic Associations Launch Campaign to Prevent Fractures
September 23, 2002
- Initial Sales of Bisphosphonate Disappointing
September 23, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 23, 2002
- IFPW General Membership Meeting Held in Monte Carlo
September 23, 2002
- REGULATORY NEWS IN BRIEF
September 23, 2002
- Banyu to Boost Its Sales to \300 Bil. by FY2007: Mr Nagasaka
September 23, 2002
- Cancer Risk Increases with Level of Alcohol Consumption: Korosho Report
September 23, 2002
- Korosho Calls For Closer Management of Radiation Devices
September 23, 2002
- Makers Called On to Take Measures to Prevent Drug Misuse
September 23, 2002
- BI, Pfizer to Start Long-term Clinical Trial for Spiriva
September 23, 2002
- Sysmex Doubles Production Capacity
September 23, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…